Attorney Docket No.: 15730.02039.US25/2039E
`
`IN THE UNITED STATES PATENT AND TRADEMARK OFFICE
`
`Applicant
`Serial No.
`Filed
`
`Title
`
`: Helenekef al.
`:
`14/683,415
`: April 10, 2015
`
`1673
`:
`Art Unit
`: Lau, Jonathan S.
`Examiner
`:
`9155
`Conf. No.
`:
`26263
`Cust. No.
`: METHODS AND COMPOSITIONS FOR ADMINISTRATION OF
`IRON
`
`Mail Stop Amendment
`Commissioner for Patents
`P.O. Box 1450
`Alexandria, VA 22313-1450
`
`SUPPLEMENTAL INFORMATION DISCLOSURE STATEMENTIN
`ACCORDANCEWITH 37 C.FE.R. §§ 1.97-1.98
`
`DearSir:
`
`Because this Supplemental Information Disclosure Statementis filed before the
`
`receipt of a First Office Action on the Merits for the above-captioned application, a fee is not
`required, If it is determined that a fee for filing these papers is required, the Commissioneris
`authorized to charge Deposit Account No. 50-0911.
`
`In accordance with the duty of disclosure imposed by 37 C.F.R. §1.56 to inform the
`
`Patent Office of all information known by Applicant or Applicant's representative that may
`
`be material to the examination of the subject application, Applicant's representative hereby
`provides this Supplemental Information Disclosure Statement that is prepared in accordance
`with 37 C.F.R. §§1.97-1.98. Forms PTO-1449 (5 pages) and copics of the cited non-U.S,
`
`patent documents are provided herewith in connection with the above-captioned application.
`
`The documents cited on the Forms PTO-1449 are in the English language. Hence, in
`
`accordance with the requirements of 37 C.F.R. § 1.98, no further explanation of the listed
`
`items is necessary.
`
`Although these documents and applications are made knownto the Patent and
`
`Trademark Office in compliance with Applicant's duty of disclosure, such disclosure is not to
`
`be construed as an admission by Applicant or Applicant's representative that any of the
`
`documents, singly or in any combination thereof, is effective as prior art against the subject
`
`application. In accordance with 37 C.F.R. § 1.97(g) and (h), the filing of this Supplemental
`
`Information Disclosure Statement shall not be construed to mean that a search has been made
`
`or that no other material information as defined in 37 C.F.R. § 1.56(b) cxists.
`
`CERTIFICATE OF TRANSMISSION VIA EFS-WEB
`
`Ex. 3002
`Ex. 3002
`PGR2020-00009
`PGR2020-00009
`
`Thereby certify that this paper is being transmitted via the
`Electronic Filing System (EFS-WEB)to the United States Patent
`and Trademark
`Officc January 27, 2017.
`
`Robert Chomik
`
`

`

`Applicant
`Serial No.
`Filed
`
`: Helenek etal.
`:
`14/683,415
`: April 10, 2015
`
`Attorney Docket No.: 15730.02039.0S825/2039E
`Supplemental Information Disclosure Statement
`
`Applicant respectfully requests that the Examiner review the foregoing documents
`and they be madeof recordin the file history of the aboyé-captiowed application.
` Respectful
`itted,
`
`
`
`Stephanie Seidman
`Reg. No. 33,779
`
`Attorney Docket No. 15730.02039.U0S825/2039E
`Addressall correspondence to: 13565
`Stephanie Seidman
`Dentons US LLP
`4655 Executive Dr., Ste. 700
`San Diego, California 92121
`Telephone: (619) 595-8010
`Facsimile:
`(619) 595-8135
`email: stephanie.seidman@dentons.com
`
`-2-
`
`

`

`Sheet _1 of __5_
`
`Substitute Form PTO-1449 U.S. Department of Commerce|Attorney Docket No. Application No.
`
`
`
`
`(Modified) Patent and Trademark Office|15730.02039.US825/2039E 14/683,415
`
`List of Patents and Publications for Applicant’s
`Information Disclosure Statement
`(37 CFR §1.98(b))
`
`Group Art Unit
`1673
`
`Heleneke7al.
`FilingDate
`April 10, 2015
`U.S. Patent Documents
`Filing Date
`Publication
`Document
`Desig.
`Examiner
`
`
`
`
`
`Initial Class|SubclassID Number Date Patentee lf Appropriate
`
`
`
`
`7,754,702
`07/13/10
`Heleneketal.
`01/08/2007
`
`8,431,549
`
`04/03/13
`
`Heleneketal.
`
`05/25/2010
`
`Foreign Patent Documents or Published Foreign Patent Applications
`
`Examiner|Desig. Document Publication Country or Patent Translation
`
`
`
`Initial
`ID
`Number
`Date
`Office
`ES
`
`None
`
`Other Documents (include Author, Title, Date, and Place of Publication)
`Examiner|Desig.
`Initial
`ID
`Document
`Letter/Written Disclosure of the initial Information Disclosure Statement for the above-referenced
`ho safetyprofilesinchronickidneydisease,"KidneyInternational73:528-530(2008).
`application, filed herewith on Janua
`Auerbachet al., "Low-molecular weightiiron dextran and iron sucrose have similar comparative
`||ae|DanielsonB.G., "Structure, chemistry, and pharmacokinetics ofintravenous iron agents," J Am Soc
`
`|aK|MacDougall et al., "Use ofintravenous iron supplementation in chronic kidney disease" Iranian J|aK|Mace Dis 7(1):9-22 (2013).
`|aL|MacDougall LC., "Stratcgics for iron supplementation: Oral versus intravenous" Kidney|aL|MacDougall 55(69): S61-66 (1999).
`
`Reinisch et al., "A randomized, open-label, non-inferiority study of intravenous iron isomaltoside
`1,000 (Monofer) compared with oral iron for treatment of anemia in IBD (PROCEED)," Am J
`Gastroenterol 108(12):1877-88 (2013).
`
`stable hemoglobin levels in inflammatory bowel disease," Scand J Gastroenterol 50(10):1226-1233
`
`conformance and not considered. Include copy of this form with next communication to applicant.
`
`Nephrol 15 Suppl 2:593-S98 (2004).
`Decision of the Technical Board of Appeal, dated March 1, 2006, in connection with European
`Patent No. 0679508, 17 pages.
`|AG Fisons Pharmaceuticals, "Imferon," US drug monograph,2 pages (1989).
`Jahn et al., "A comparative study of the physiochemical properties of iron isomaltoside 1000
`(Monofer), a new intravenous iron preparation andits clinical implications," European J of
`Pharmaceutics and Biopharmaceutics 78:480-491 (2011).
`Johanssonet al., "Intravenous iron isomaltoside 1000 (Monofer®) reduces postoperative anaemia in
`preoperatively non-anaemic patients undergoing elective or subacute coronary artery bypass graft,
`valve replacement or a combination thereof: a randomized double-blind placebo-controlled clinical
`
`trial (the PROTECTtrial)," Vox Sang 109(3):257-266 (2015).
`Kulnigget al., "A novel intravenous iron formulation for treatment of anemia in inflammatory
`boweldisease: the ferric carboxymallose (FERINJECT) randomized controlled trial," Am J
`Gastroenterol 103(5):1182-1192 (2008).
`
`
`
`jan|Saetal., "A 1-yeartrialofrepeatedhigh-doseintravenousironisomaltoside 1000tomaintainjan fsa
`
`
`Syner-Med, "Summary of Product Characteristics; Ferinject," (2009), 8 pages.
`Office Action, mailed Dec. 15, 2009, in connection with U.S. Patent Application Serial No.
`11/620,986, 21 pages.
`
`|ag|Response: dated Jan. 08, 2010, in connection with U.S. Patent Application Serial No. 11/620,986,
`
`13 pages.
`
`Examiner Signature
`
`Date Considered
`
`EXAMINER:
`
`Initial if citation considered, whetheror not citation is in conformance with MPEP 609; Draw line through citation if not in
`
`

`

`Sheet _2 of _5_
`
`
`Substitute Form PTO-1449 U.S. Department of Commerce|Attorney Docket No. Application No.
`
`
`
`
`(Modified) Patent and Trademark Office|15730.02039.US825/2039E 14/683,415
`
`List of Patents and Publications for Applicant’s
`Information Disclosure Statement
`(37 CFR §1.98(b))
`
`conformance and not considered. Include copy of this form with next communication to applicant.
`
`Heleneke7al.
`Group Art Unit
`FilingDate
`1673
`April 10, 2015
`Notice of Allowance, mailed April 5, 2010, in connection with U.S. Patent Application Serial No.
`
`11/620,986, 12 pages.
`Petition for Inter Partes Review of U.S. Patent No. 7,754,702, mailed June 24, 2015, in connection
`with U.S. Patent Application Serial No. 11/620,986, 65 pages.
`Patent Owner Preliminary Response, dated Oct. 12, 2015, in connection with U.S. Patent
`Application Serial No. 11/620,986 (U.S. Patent No. 7,754,702), 39 pages.
`Decision, entered Jan. 08, 2016, in connection with U.S. Patent Application Serial No. 11/620,986
`(U.S. Patent No. 7,754,702), 20 pages.
`Order Conduct of the Proceedings, mailed Mar. 11, 2016, in connection with U.S. Patent
`Application Serial No. 11/620,986 (U.S. Patent No. 7,754,702), 6 pages.
`Patent Owner Response, mailed Mar. 29, 2016, in connection with U.S. Patent Application Serial
`
`No. 11/620,986 (U.S. Patent No. 7,754,702), 47 pages.
`Patent Owner Exhibit List as of March 29, 2016, mailed Mar. 29, 2016, in connection with U.S.
`Patent Application Serial No. 11/620,986 (U.S. Patent No. 7,754,702), 7 pages.
`Motion to Amend, mailed Mar. 29, 2016, in connection with U.S. Patent Application Serial No.
`11/620,986 (U.S. Patent No. 7,754,702), 48 pages.
`Petitioner's Notice of Objections to Evidence, mailed Apr. 5, 2016, in connection with U.S. Patent
`Application Serial No. 11/620,986 (U.S. Patent No. 7,754,702), 5 pages.
`Corrected Patent Owner Exhibit List as of April 25, 2016, mailed Apr. 25, 2016, in connection with
`U.S. Patent Application Serial No. 11/620,986 (U.S. Patent No. 7,754,702).7 pages.
`Corrected Motion to Amend, mailed Apr. 25, 2016, in connection with U.S. Patent Application
`
`Serial No. 11/620,986 (U.S. Patent No. 7,754,702), 48 pages.
`Petitioner's Reply to Patent Owner Response, dated June, 20, 2016, in connection with U.S. Patent
`Application Serial No. 11/620,986 (U.S. Patent No. 7,754,702), 32 pe
`Petitioner's Opposition to Patent Owner's Motion to Amend, dated Juneie 20, 2016, in connection
`with U.S. Patent Application Serial No. 11/620,986 (U.S. Patent No. 7,754,702), 31
`.
`Objections to Petitioner's Reply and Opposition Evidence, dated June 27, 2016, in connection with
`U.S. Patent Application Scrial No. 11/620,986 (U.S. Patent No. 7,754,702), 5 pages.
`Patent Owncr Reply to Opposition to Motion to Amend, dated July 19, 2016, in connection with
`U.S. Patent Application Serial No. 11/620,986 (U.S. Patent No. 7,754,702), 20
`.
`Patent Owner Motion to Exclude, dated Aug. 09, 2016, in connection with U.S. Patent Application
`
`Serial No. 11/620,986 (U.S. Patent No. 7,754,702), 19 pages.
`Order Conductof the Proceedings, dated Aug. 19, 2016, in connection with U.S. Patent Application
`Serial No. 11/620,986 (U.S. Patent No. 7,754,702), 3 pages.
`Order Trial Hearing, dated Aug. 22, 2016, in connection with U.S. Patent Application Serial Nos.
`11/620,986 (U.S. Patent No. 7,754,702), 5 pages.
`Petitioner's Opposition to Patent Owner's Motion to Exclude, dated Aug. 23, 2016, in connection
`with U.S. Patent Application Scrial No. 11/620,986 (U.S. Patent No. 7,754,702), 19 pages.
`Patent Owncr Reply to Opposition to Motion to Exclude, dated Aug. 30, 2016, in connection with
`U.S. Patent Application Serial No. 11/620,986 (U.S. Patent No. 7,754,702), 9 pages.
`Record of Oral Hearing, dated Nov. 03, 2016, in connection with U.S. Patent Application Serial No.
`
`11/620,986 (U.S. Patent No. 7,754,702), 104 pages.
`Final Written Decision, dated Jan. 4, 2017, in connection with U.S. Patent Application Serial No.
`11/620,986 (U.S. Patent No. 7,754,702), 52
`Restriction Requirement, dated March 23, 2012, in connection with U_S. Patent Application Serial
`No. 12/787,283, 7 pages.
`Response, dated April 19, 2012, to Restriction Requirement, mailed March 23, 2012, in connection
`with U.S. Patent Application Scrial No. 12/787,283, 4 pages.
`Office Action, mailed Junc 6, 2012, in connection with U.S. Patent Application Scrial No.
`12/787,283, 13 pages.
`Response, dated Dec. 6, 2012, to Office Action, mailed June 6, 2012, in connection with U.S. Patent
`
`Application Serial No. 12/787,283, 34 pages.
`Date Considered
`
`Examiner Signature
`
`EXAMINER:
`
`Initial if citation considered, whetheror not citation is in conformance with MPEP 609; Draw line through citation if not in
`
`

`

`
`
`Sheet 3 of _5
`
`Substitute Form PTO-1449 U.S. Department of Commerce|Attorney Docket No. Application No.
`
`
`
`
`(Modified) Patent and Trademark Office|15730.02039.US825/2039E 14/683,415
`
`List of Patents and Publications for Applicant’s
`Information Disclosure Statement
`(37 CFR §1.98(b))
`
`conformance and not considered. Include copy of this form with next communication to applicant.
`
`Heleneke7al.
`Group Art Unit
`FilingDate
`1673
`April 10, 2015
`Applicant-Initiated Interview Summary, mailed Feb. 6, 2013, in connection with U.S. Patent
`
`Application Serial No. 12/787,283, 4 pages.
`Notice of Allowance, mailed Feb. 28, 2013, in connection with U.S. Patent Application Serial No.
`12/787,283, 14 pages.
`Petition for Inter Partes Review of U.S. Patent No. 8,431,549, dated June 24, 2015, in connection
`with U.S. Patent Application Serial No. 12/787,283, 67 pages.
`Patent Owner Preliminary Response, dated Oct. 12, 2015, in connection with U.S. Patent
`Application Scrial No. 12/787,283 (U.S. Patent No. 8,431,549), 65 pages.
`Order Conduct of the Proceeding, entered Oct. 14, 2015, in connection with U.S. Patent Application
`Serial No. 12/787,283 (U.S. Patent No. 8,431,549), 4 pages.
`Notice of Responsein licu of Motion, dated Oct. 20, 2015, in connection with U.S. Patent
`
`Application Serial No. 12/787,283 (U.S. Patent No.,43 1,549), 4 pages.
`Petitioner's Objection to Patent Owner Response in Lieu of Motion, dated Oct. 30, 2015, in
`connection with U.S. Patent Application Serial No. 12/787,283 (U.S. Patent No. 8,431,549), 4
`pages.
`Inter Partes Review Decision, entered Jan. 08, 2016, in connection with U.S. Patent Application
`Serial No. 12/787,283 (U.S. Patent No. 8,431,549), 24 pages.
`Request for Rehearing, dated Jan. 22, 2016, in connection with U.S. Patent Application Serial No.
`12/787,283 (U.S. Patent No. 8,431,549), 8 pages.
`Patent Owner Objections to Evidence, dated Jan. 27, 2016, in connection with U.S. Patent
`
`Application Serial No. 12/787,283 (U.S. Patent No. 8,431,549), 4 pages.
`Revised Patent Owner Notice of Deposition of Dr. Linhardt, dated Feb. 19, 2016, in connection
`with U.S. Patent Application Serial No. 12/787,283 (U.S. Patent No. 8,431,549), 3 pages.
`Decision Denying Petitioner's Request for Rehearing, entered Feb. 26, 2016, in connection with
`U.S. Patent Application Serial No. 12/787,283 (U.S. Patent No. 8,431,549), 5 pages.
`Order re Conference Call on March 09, 2016, entered Mar. 11, 2016, in connection with U.S. Patent
`Application Serial No. 12/787,283 (U.S. Patent No. 8.431,549), 6
`.
`Patent Owncr Exhibit List as of July 19, 2016 in connection with U.S. Patent Application Scrial No.
`12/787,283 (U.S. Patent No. 8,43 1,549), 7 pages.
`Patent Owner Reply to Opposition to Motion to Amend, dated July 19, 2016, in connection with
`
`U.S. Patent Application Serial No. 12/787,283 (U.S. Patent No. 8,431,549), 20 pages.
`Order Trial Hearing, dated Aug. 22, 2016, in connection with U.S. Patent Application Serial No.
`12/787,283 (U.S. Patent No. 8,431,549), 5
`.
`Record of Oral Hearing, dated Nov. 03, 2016, in connection with U.S. Patent Application Serial No.
`12/787,283 (U.S. Patent No. 8,431,549), 104 pages.
`Inter Partes Review Final Written Decision, filed Dec. 28, 2016, in connection with U.S. Patent
`Application Serial No. 12/787,283 (U.S. Patent No. 8,431,549), 28 pages.
`Restriction Requirement, mailed Dec. 30, 2013, in connection with U.S. Patent Application Scrial
`No. 13/847,254, 7 pages.
`Response, dated Feb. 28, 2014, to Restriction Requirement, mailed Dec. 30, 2013, in connection
`with U.S. Patent Application Serial No. 13/847,254, 4
`.
`Office Action, mailed Apr. 07, 2014, in connection with U.S. Patent Application Serial No.
`13/847,254, 17
`Response, dated July 03, 2014, to Office Action, mailed Apr. 07, 2014, in connection with U.S.
`Patent Application Serial No. 13/847,254, 18 pages.
`Office Action, mailed Oct. 14, 2014, in connection with U.S. Patent Application Serial No.
`13/847,254, 14 pages.
`Office Action, mailed Feb. 7, 2014, in connection with U.S. Patent Application Scrial No.
`14/100,717, 15 pages.
`Response, filed June 9, 2014, to Office Action, mailed Feb. 7, 2014, in connection with U.S. Patent
`
`Application Serial No. 14/100,717, 19 pages.
`
`Examiner Signature
`
`Date Considered
`
`EXAMINER:
`
`Initial if citation considered, whetheror not citation is in conformance with MPEP 609; Draw line through citation if not in
`
`

`

`Sheet _4 of _5_
`
`Substitute Form PTO-1449 U.S. Department of Commerce|Attorney Docket No. Application No.
`
`
`
`
`(Modified) Patent and Trademark Office|15730.02039.US825/2039E 14/683,415
`
`List of Patents and Publications for Applicant’s
`Information Disclosure Statement
`(37 CFR §1.98(b))
`
`conformance and not considered. Include copy of this form with next communication to applicant.
`
`Heleneke7al.
`Group Art Unit
`FilingDate
`1673
`April 10, 2015
`Notice of Allowance, mailed Sept. 22, 2014, in connection with U.S. Patent Application Serial No.
`
`14/100,717, 14 pages.
`Petition for Inter Partes Review of U.S. Patent No. 8,895,612, filed June 24, 2015, in connection
`with U.S. Patent Application Serial No. 14/100,717, 68 pages.
`Patent Owner Preliminary Response, dated Oct. 12, 2015, to Petition for Inter Partes Review,filed
`June 24, 2015, in connection with U.S. Patent Application Serial No. 14/100,717 (U.S. Patent No.
`8,895,612), 70 pages.
`Decision DenyingInstitution of Intcr Partes Review, centered Jan. 8, 2016, in connection with U.S.
`Patent Application Serial No. 14/100,717 (U.S. Patent No. 8,895,612), 23 pages.
`Response, dated May 17, 2013, to Office Action issued in connection with Australian Patent
`
`Application No. 2007205167, 28 pages.
`Notice of Acceptance, mailed June 04, 2013, in connection with Australian Patent Application No.
`2007205167, 1 page.
`Examination Report, issued Apr. 13, 2015, in connection with Australian Patent Application No.
`2013206429, 4 pages.
`to Examination Report, issued Apr. 13, 2015, in connection with
`Response, dated Mar. 22, 2016,
`Australian Patent Application No. 2013206429, 36 pages.
`Notice of Acceptance, issued Apr. 14, 2016, in connection with Australian Patent Application No.
`2013206429, 3 pages.
`Examination Report, issued Jan. 11, 2017, in connection with Australian Patent Application No.
`
`2016205002, 5 pages.
`Response, dated July 4, 2013, to Examiner's Report, issued Jan. 4, 2013, in connection with
`Canadian Patent Application No. 2,635,894, 26 pz
`Examiner's Report, issued Oct. 17, 2013, in connection with Canadian Patent Application No.
`2,635,894, 4
`.
`Response, dated April 16, 2014, to Examiner's Report, issued Oct. 17, 2013,
`Canadian Patent Application No. 2,635,894, 33
`Examincr's Report, issucd Oct. 10, 2014, in connection with Canadian Patent Application No.
`2,635,894, 7 pages.
`in connection with
`Response, dated April 8, 2015, to Examiner's Report, issued Oct. 10, 2014,
`
`Canadian Patent Application No. 2,635,894, 30 pages.
`Examiner's Report, issued Sept. 29, 2015, in connection with Canadian Patent Application No.
`2,635,894, 8
`Response, dated March 23, 2016, to Examiner's Report, issued Sept. 29, 2015, in connection with
`CanadianPatent Application No. 2,635,894, 19 pages.
`Examiner's Report, issued May 16, 2016, in connection with Canadian Patent Application No.
`2,635,894, 8 pages.
`Response, dated Nov. 15, 2016, to Examincr's Report, issued May 16, 2016, in connection with
`Canadian Patent Application No. 2,635,894, 24 pages.
`Examination Report, issued May 10, 2011, in connection with European Patent Application No.
`07716309.5, 6
`Response, dated Dec. 14, 2012, to Examination Report, dated June 4, 2012, in connection with
`European Patent Application No. 07716309.5, 17 pages.
`Response, dated Jan. 15, 2014, to Examination Report, dated July 5, 2013, in connection with
`European Patent Application No. 07716309.5, 19 pages.
`Third Party Observations, submitted Oct. 31, 2014, and Communication pursuant to Rule 114(2)
`EPC,dated Nov. 10, 2014, in connection with European Patent Application No. 07716309.5 [Third
`party observations, Communication and cited references|, 22 pages.
`Summons to Attend Oral Proceedings, dated Feb. 9, 2015, issued in connection with European
`Patent Application No. 07716309.5, 4
`.
`Response, dated Oct. 30, 2015, to Summons to Attend Oral Proceedings, dated Feb. 9, 2015, in
`
`connection with European Patent Application No. 07716309.5, 98 pages.
`Date Considered
`
`in connection with
`
`Examiner Signature
`
`EXAMINER:
`
`Initial if citation considered, whetheror not citation is in conformance with MPEP 609; Draw line through citation if not in
`
`

`

`
`
`Sheet _5 of _5_
`
`Substitute Form PTO-1449 U.S. Department of Commerce|Attorney Docket No. Application No.
`
`
`
`
`(Modified) Patent and Trademark Office|15730.02039.U$25/2039E 14/683,415
`
`List of Patents and Publications for Applicant’s
`Information Disclosure Statement
`(37 CFR §1.98(b))
`
`Heleneke7al.
`Group Art Unit
`FilingDate
`1673
`April 10, 2015
`Third Party Observations, submitted Nov. 11, 2015, and Communication maintaining the date/time
`for oral proceedings, dated Nov. 12, 2015, in connection with European Patent Application No.
`07716309.5, 4 pages.
`Response, dated Nov. 27, 2015, to Notice Concerning the Oral Proceedings, dated Nov. 19, 2015, in
`connection with European Patent Application No. 07716309.5, 67 pages.
`Decision to Grant, dated June 23, 2016, issued in connection with European Patent Application No.
`07716309.5, 2 pages.
`Examination Report, issucd April 7, 2014, in conncction with European Patent Application No.
`13 166988.9, 4 pages.
`Response, dated Oct. 17, 2014, to Examination Report, issued April 7, 2014, in connection with
`
`European Patent Application No. 13166988.9, 13 pages.
`Third Party Observations, submitted Nov. 03, 2014, in connection with European Patent
`Application No. 13166988.9, 2 pages.
`Summons to Aitend Oral Proceedings, dated Feb. 10, 2015, in connection with European Patent
`Application No. 13166988.9, 6 pages.
`Response, dated Oct. 30, 2015, to Summons to Attend Oral Proceedings, dated Feb. 10, 2015, in
`conncction with European Patent Application No. 13166988.9, 91 pages.
`Third Party Observations, submitted Nov. 11, 2015, and Communication maintaining the date/time
`for oral proceedings, dated Nov. 12, 2015, in connection with European Patent Application No.
`
`13 166988.9, 4 pages.
`Response, dated Nov. 23, 2015, to Summons to Attend Oral Proceedings, dated Feb. 10, 2015, in
`connection with European Patent Application No. 13166988.9, 13 pages.
`Communication from the Patent Office, issued Nov. 30, 2015, in connection with European Patent
`Application No. 13166988.9, 1 page.
`Response, dated Nov. 27, 2015, in connection with EuropeanPatent Application No. 13166988.9,
`
`conformance and not considered. Include copy of this form with next communication to applicant.
`
`13166988.9, 7 pages.
`Extended European Search Report, dated Aug. 3, 2016, in connection with European Patent
`
`Application No. 16172826.6, 13 pages.
`Office Action, dated Aug. 30, 2016, in connection with Korean Patent Application No. 10-2014-
`7024469 [English translation], 7 pa
`Invalidation Request, filed June 20, 2016, in connection with Chinese Patent Application No.
`200780002006 [English translation, document as filed in Chinese and Notice of acceptance of
`invalidation request as issued in Chinese], 174 pages.
`Response, filed Aug. 23, 2016, to Invalidation Request, filed June 20, 2016, in connection with
`Chinese Patent Application No. 200780002006 [English instructions, documentas filed in Chinese
`and claims as filed in English], 118 pages.
`Notice of Oral Hearing, issued Aug. 31, 2016, in connection with Chinese Patent Application No.
`
`200780002006 [English translation], 5 pages.
`Post Hearing Observations, filed Dec. 8, 2016, on Response, filed Aug. 23, 2016, to Invalidation
`Request, filed June 20, 2016,in connection with Chinese Patent Application No. 200780002006
`[English instructions for response, document as filed in Chinese and English translation of filed
`claims], 57 pages.
`
`Examiner Signature
`
`Date Considered
`
`EXAMINER:
`
`Initial if citation considered, whetheror not citation is in conformance with MPEP 609; Draw line through citation if not in
`
`